Preventing torsades de pointes by careful cardiac monitoring in hospital settings

AACN Advanced Critical Care

Volumn 18, Issue 3, 2007, Pages 285-293

  Sommargren, Claire E ^a   Drew, Barbara J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

QT interval; QTc; Repolarization; Torsades de pointes

Indexed keywords

DOCUMENTATION; ELECTROCARDIOGRAPHY; HEART RATE; HEART VENTRICLE TACHYCARDIA; HUMAN; INTENSIVE CARE; LONG QT SYNDROME; MATHEMATICS; MEDICAL RECORD; METHODOLOGY; MONITORING; NURSE ATTITUDE; NURSING; NURSING ASSESSMENT; PATIENT SELECTION; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SUPRAVENTRICULAR TACHYCARDIA; TORSADE DES POINTES;

CRITICAL CARE; DOCUMENTATION; ELECTROCARDIOGRAPHY; HEART RATE; HUMANS; LONG QT SYNDROME; MATHEMATICS; MONITORING, PHYSIOLOGIC; NURSE'S ROLE; NURSING ASSESSMENT; NURSING RECORDS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; TACHYCARDIA, SUPRAVENTRICULAR; TACHYCARDIA, VENTRICULAR; TORSADES DE POINTES;

EID: 38449110147     PISSN: 15597768     EISSN: 15597768     Source Type: Journal    
DOI: 10.1097/01.AACN.0000284429.45534.4a     Document Type: Review

References (11)

1. Lo SL, Drew BJ. Lead selection for QT interval measurement for bedside ECG monitoring. Circulation. 2002;106:II-489.
2. Moss AJ, Zareba W, Benhorin J, et al. ISHNE guidelines for electrocardiographic evaluation of drug-related QT prolongation and other alterations in ventricular repolarization: task force summary. A report of the Task Force of the International Society for Holter and Noninvasive Electrocardiology (ISHNE), Committee on Ventricular Repolarization. Ann Noninvasive Electrocardiol. 2001;6:333-341.
3. Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy. 2003;23:881-908.
4. Anderson ME, Al-Khatib SM, Roden DM, Califf RM, for the Duke Clinical Research Institute/American Heart Journal Expert Meeting on Repolarization Changes. Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J. 2002;144:769-781.
5. Bazett HC. An analysis of the time-relations of the electrocardiograms. Heart. 1920;7:353-362.
6. Drew BJ, Califf RM, Funk M, et al. Practice standards for electrocardiographic monitoring in hospital settings. Circulation. 2004;110:2721-2746.
7. Drew BJ, Funk M. Practice standards for ECG monitoring in hospital settings: executive summary and guide for implementation. Crit Care Nurs Clin N Am. 2006;18:157-168.
8. Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labeling. Drug Saf. 2001;24:323-352.
9. Zareba W, Moss AJ. AT interval and its drug-induced prolongation. In: Gussak I, Antzelevitch C, Hammill SC, Shen WK, Bjerregaard P, eds. Cardiac Repolarization: Bridging Basic and Clinical Science. Totowa, NJ: Humana Press; 2003:311-328.
10. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-1022.
11. Sommargren CE, Zaroff JG, Banki NM, et al. High frequency of cardiac depolarization and repolarization abnormalities in subarachnoid hemorrhage: evidence for the catecholamine hypotheses? Circulation. 2003;108:IV-362.